Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program


NEW YORK, April 24, 2019 /PRNewswire/ -- Emendo Biotherapeutics Inc today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of the transaction, Emendo will receive an investment in convertible notes from Takeda Ventures, Inc., the corporate venture arm of Takeda. The funds will be used to further advance Emendo's novel nuclease gene editing discovery platform and proprietary product development programs.

The licensing option agreement grants Takeda the option to use OMNI, Emendo's proprietary nuclease program, to edit two genes as part of its research and development efforts. Further, Emendo will apply its novel gene editing engineering platform to optimize the OMNI nuclease to have the highest specificity and activity on Takeda's chosen genes.

"Extending our investment in Emendo and licensing its nuclease discovery platform and gene editing technology is another example of Takeda's commitment to investing in transformative advances in science via mutally advantageous partnerships," said Takeda Ventures Senior Partner Rob Woodman.

The notes will be converted in Emendo's planned B round financing intended to allow the company to advance its high precision gene editing biotherapies into initial clinical trials.  Emendo is moving several preclinical programs through optimization, in preparation for moving towards the clinic in a number of promising clinical indications. 

Emendo's gene editing program, OMNI, enables extremely specific gene editing which minimizes off target cuts and allows for highly focused therapeutic intervention in complex genetic diseases. 

Emendo's CEO, David Baram, says "We're pleased to be working with an innovative global pharmaceutical leader such as Takeda. This agreement further positions Emendo as a leading, next-generation, high-precision, gene editing company and promotes its allele specific editing programs that can potentially cure severe genetic disorders."

About Emendo

Emendo is a genome editing company developing genetic medicines and cell therapies for severe diseases. Emendo's cutting-edge technology is based on its proprietary protein engineering and selection platforms, designed to generate ultra-specific and highly active CRISPR OMNI nucleases, carefully optimized per target sequence for generating safe and effective genetic solution. Emendo was established in 2015 with investments by OrbiMed Advisors LLP And Takeda Ventures, Inc. the corporate venture arm of Takeda Pharmaceuticals Limited.

For more information:

David Baram, CEO
David@emendobio.com
+972-54-4907749


These press releases may also interest you

at 21:33
Healthcare providers are focused on delivering care. That means always seeking better ways to improve patient outcomes, make reporting easier, and meet financial goals. It's a big job that never ends. That's why  Prista Corporation Chief Mission...

at 21:18
Global Vitamin D Testing Market: About this market Vitamin D is needed to maintain serum calcium and phosphate concentration to regularize the mineralization of bone and tooth. This vitamin D testing market analysis considers sales from both...

at 21:07
Digital Therapeutics and Their Impact on HealthcareSummaryRead the full report: https://www.reportlinker.com/p05795614/?utm_source=PRN Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx)...

at 21:00
Is there some way to bring a software as a medical device (SaMD) product to market faster? The answer is yes, with the Software Precertification Program. The pre-cert pathway regulatory model expedites pre-market approval while assessing the safety...

at 20:50
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2019 on Thursday, August 1, 2019, following the close of the market. The company will discuss...

at 20:45
Immix Biopharma, Inc--a clinical-stage biopharmaceutical company developing next-generation cancer therapies--announced today that it received a letter from the FDA authorizing it to proceed with expanding its phase 1b/2a clinical trial of IMX-110 to...



News published on 24 april 2019 at 04:00 and distributed by: